Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Allergists (US)

Articles with lock require a subscription to GLG News | Request a free trial
October 6, 2008
Superinfection
Analysis of: 'Superbugs' That Strike the Sickest Patients | online.wsj.com
Author: GLG Expert Contributor
With new Medicare payment guidelines for what will be paid- these infections will clearly need addressing. A nosocomial infection can lenghten the hospital stay. If Medicare doesn't pay for this, many institutions be be hard pressed to stay solvent.
October 6, 2008
Need to use these meds correctly
Analysis of: Anemia Drugs Linked to Stroke Study Deaths: FDA | health.usnews.com
Author: GLG Expert Contributor
This is just another issue with these drugs. They need to be used appropriately in all patients that may be candidates for their use.
October 6, 2008
About time !
Analysis of: Drug maker plans to disclose payments to doctors | news.yahoo.com
Author: GLG Expert Contributor
How many physicians will allow themseves to be a "hired gun" for the right price? It is very disturbing to the general public and erodes their confidence in the profession in general. This needs to stop or be made public!
October 6, 2008
Disturbing but not so surpiring
Analysis of: Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
Author: GLG Expert Contributor
We see many drugs with issues that come to light only in post-marketing studies and reports. Big Pharma is in it for the profit- undfortinately only positive studies  will allow this.
October 2, 2008
COPD Drugs - Some safer than others
Analysis of: COPD Medicines: Risky or Safe? | www.webmd.com
Author: GLG Expert Contributor
In a recent article it is noted that for users of Ipatropium bromide there was an increase in all death and cardiac death in the group studied.  Theoretically at doses normally used there is not much of a corresponding mechanistic risk.  Therefore at this time additional study must be done...
September 22, 2008
BAD news
Analysis of: FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta | www.fda.gov
Author: GLG Expert Contributor
Patients will be reluctant to take and physicians are much less likely to use till this issue is clarified.
July 18, 2008
What do you expect in hard economic times?
Analysis of: Patients Curb Prescription Spending | online.wsj.com
Author: GLG Expert Contributor
With the economy in recession, whether we are willing to say it or not; with increased cost of food, gas, etc.; what do you expect. Patients are askiing and getting generics. This is on top of most PBM and managed care companies whose P4P includes generic use and stress this to the patient.
July 18, 2008
Too much of a good thing
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor
This report suggest that there is a point in therapy where we start seiing negative effects from the use of bisphosphanates. There needs to be guidelines on length of therapy. Too long may lead to adverse effects.
July 11, 2008
Desperate times- desperate measures
Analysis of: 8-Year-Olds on Statins? A New Plan Quickly Bites Back | www.nytimes.com
Author: GLG Expert Contributor
This recommedation is just a reflection of how out of hand the crisis of obesity and metabolic syndrome/diabetes is in our youth. We all need to wake up and do something.
July 3, 2008
yes!
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: GLG Expert Contributor
When drug studies are done some unexpected findings emerge. If these results can show promise and expand drug use they should be persued as the cost will likely be less than developing a whole new drug.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 437

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203